Presentation is loading. Please wait.

Presentation is loading. Please wait.

Treatment strategy for chylothorax after pulmonary resection and lymph node dissection for lung cancer  Kimihiro Shimizu, MD, Junji Yoshida, MD, Mituyo.

Published byBrigitte Corbeil Modified over 5 years ago

Similar presentations

Presentation on theme: "Treatment strategy for chylothorax after pulmonary resection and lymph node dissection for lung cancer  Kimihiro Shimizu, MD, Junji Yoshida, MD, Mituyo."— Presentation transcript:

1 Treatment strategy for chylothorax after pulmonary resection and lymph node dissection for lung cancer  Kimihiro Shimizu, MD, Junji Yoshida, MD, Mituyo Nishimura, MD, Kazuya Takamochi, MD, Rie Nakahara, MD, Kanji Nagai, MD  The Journal of Thoracic and Cardiovascular Surgery  Volume 124, Issue 3, Pages (September 2002) DOI: /mtc Copyright © 2002 American Association for Thoracic Surgery Terms and Conditions

2 Fig. 1 Chest tube drainage during the first 24 hours after complete oral intake cessation and TPN. Statistically significant difference was observed between groups (P <.0001 by t test). The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /mtc ) Copyright © 2002 American Association for Thoracic Surgery Terms and Conditions

3 Fig. 2 Treatment strategy for postoperative chylothorax. COIC, Complete oral intake cessation. The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /mtc ) Copyright © 2002 American Association for Thoracic Surgery Terms and Conditions

Download ppt "Treatment strategy for chylothorax after pulmonary resection and lymph node dissection for lung cancer  Kimihiro Shimizu, MD, Junji Yoshida, MD, Mituyo."

Similar presentations

Resection of ascending aortic aneurysm without use of an interposition aortic graft John S. Ikonomidis, MD, PhD, FRCS(C), Abe DeAnda, MD, D.Craig Miller,

Resection of ascending aortic aneurysm without use of an interposition aortic graft John S. Ikonomidis, MD, PhD, FRCS(C), Abe DeAnda, MD, D.Craig Miller,
Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: Activation of the mitochondria-dependent death-signaling.

Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: Activation of the mitochondria-dependent death-signaling.
Pathologic N1 non-small cell lung cancer: Correlation between pattern of lymphatic spread and prognosis Alessandro Marra, MD, PhD, Ludger Hillejan, MD,

Pathologic N1 non-small cell lung cancer: Correlation between pattern of lymphatic spread and prognosis Alessandro Marra, MD, PhD, Ludger Hillejan, MD,
Limited resection trial for pulmonary ground-glass opacity nodules: Fifty-case experience  Junji Yoshida, MD, Kanji Nagai, MD, Tomoyuki Yokose, MD, Mitsuyo.

Limited resection trial for pulmonary ground-glass opacity nodules: Fifty-case experience  Junji Yoshida, MD, Kanji Nagai, MD, Tomoyuki Yokose, MD, Mitsuyo.
Max B. Mitchell, MD  The Journal of Thoracic and Cardiovascular Surgery 

Max B. Mitchell, MD  The Journal of Thoracic and Cardiovascular Surgery 
Lost in translation The Journal of Thoracic and Cardiovascular Surgery

Lost in translation The Journal of Thoracic and Cardiovascular Surgery
Stephen R. Broderick, MD, MPHS 

Stephen R. Broderick, MD, MPHS 
The eighth edition TNM stage classification for lung cancer: What does it mean on main street?  Frank C. Detterbeck, MD  The Journal of Thoracic and Cardiovascular.

The eighth edition TNM stage classification for lung cancer: What does it mean on main street?  Frank C. Detterbeck, MD  The Journal of Thoracic and Cardiovascular.
Limited resection trial for pulmonary ground-glass opacity nodules: Fifty-case experience  Junji Yoshida, MD, Kanji Nagai, MD, Tomoyuki Yokose, MD, Mitsuyo.

Limited resection trial for pulmonary ground-glass opacity nodules: Fifty-case experience  Junji Yoshida, MD, Kanji Nagai, MD, Tomoyuki Yokose, MD, Mitsuyo.
One in every 14 patients with early-stage lung cancer is not being treated!  Benny Weksler, MD, MBA  The Journal of Thoracic and Cardiovascular Surgery 

One in every 14 patients with early-stage lung cancer is not being treated!  Benny Weksler, MD, MBA  The Journal of Thoracic and Cardiovascular Surgery 
It is not just about surgery versus stereotactic ablative radiotherapy, it is about curing as many patients with lung cancer as possible  Alessandro Brunelli,

It is not just about surgery versus stereotactic ablative radiotherapy, it is about curing as many patients with lung cancer as possible  Alessandro Brunelli,
Lung cancer screening: No more excuses

Lung cancer screening: No more excuses
Thoracoscopic management of postoperative esophageal leak

Thoracoscopic management of postoperative esophageal leak
Ground glass opacity of the lung: The veil that needs lifting

Ground glass opacity of the lung: The veil that needs lifting
Predictive Factors for Local Recurrence of Resected Colorectal Lung Metastases  Satoshi Shiono, MD, Genichiro Ishii, MD, Kanji Nagai, MD, Junji Yoshida,

Predictive Factors for Local Recurrence of Resected Colorectal Lung Metastases  Satoshi Shiono, MD, Genichiro Ishii, MD, Kanji Nagai, MD, Junji Yoshida,
Murray H. Kwon, MD  The Journal of Thoracic and Cardiovascular Surgery 

Murray H. Kwon, MD  The Journal of Thoracic and Cardiovascular Surgery 
The Incidence and Management of Postoperative Chylothorax After Pulmonary Resection and Thoracic Mediastinal Lymph Node Dissection  Ayesha S. Bryant,

The Incidence and Management of Postoperative Chylothorax After Pulmonary Resection and Thoracic Mediastinal Lymph Node Dissection  Ayesha S. Bryant,
Surgery for acute type A aortic dissection on oral anticoagulants: Being the dispatcher of a 911 call  Ourania Preventza, MD, Arthur Bracey, MD  The Journal.

Surgery for acute type A aortic dissection on oral anticoagulants: Being the dispatcher of a 911 call  Ourania Preventza, MD, Arthur Bracey, MD  The Journal.
Tomohiro Maniwa, MD, Yukihito Saito, MD, Hiroyuki Kaneda, MD 

Tomohiro Maniwa, MD, Yukihito Saito, MD, Hiroyuki Kaneda, MD 
New treatment approaches create new disease processes: A short guide on how to reduce unexpected events to a minimum  Martin Czerny, MD, MBA  The Journal.

New treatment approaches create new disease processes: A short guide on how to reduce unexpected events to a minimum  Martin Czerny, MD, MBA  The Journal.

Similar presentations

Ads by Google